These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 34015520)
1. Comparison of glycoprofiles of rituximab versions licensed for sale in India and an analytical approach for quality assessment. Kaur T; Shukla BN; Yadav VK; Kulkarni MJ; Rao A J Proteomics; 2021 Jul; 244():104267. PubMed ID: 34015520 [TBL] [Abstract][Full Text] [Related]
2. Comparability study of Rituximab originator and follow-on biopharmaceutical. Montacir O; Montacir H; Eravci M; Springer A; Hinderlich S; Saadati A; Parr MK J Pharm Biomed Anal; 2017 Jun; 140():239-251. PubMed ID: 28371718 [TBL] [Abstract][Full Text] [Related]
3. Multiple-parallel-protease digestion coupled with high-resolution mass spectrometry: An approach towards comprehensive peptide mapping of therapeutic mAbs. Pradhan G; Sneha JM; Sonwane BP; Santhakumari B; Rao A; Kulkarni MJ J Proteomics; 2021 Feb; 232():104053. PubMed ID: 33238212 [TBL] [Abstract][Full Text] [Related]
4. Glycosylation of biosimilars: Recent advances in analytical characterization and clinical implications. Duivelshof BL; Jiskoot W; Beck A; Veuthey JL; Guillarme D; D'Atri V Anal Chim Acta; 2019 Dec; 1089():1-18. PubMed ID: 31627805 [TBL] [Abstract][Full Text] [Related]
5. Hydrophilic Interaction Chromatography Hyphenated with Mass Spectrometry: A Powerful Analytical Tool for the Comparison of Originator and Biosimilar Therapeutic Monoclonal Antibodies at the Middle-up Level of Analysis. D'Atri V; Fekete S; Beck A; Lauber M; Guillarme D Anal Chem; 2017 Feb; 89(3):2086-2092. PubMed ID: 28208257 [TBL] [Abstract][Full Text] [Related]
6. Comparison of originator and biosimilar monoclonal antibodies using HRMS, Fc affinity chromatography, and 2D-HPLC. Reinders LMH; Klassen MD; Teutenberg T; Jaeger M; Schmidt TC Anal Bioanal Chem; 2022 Sep; 414(23):6761-6769. PubMed ID: 35895102 [TBL] [Abstract][Full Text] [Related]
7. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. Visser J; Feuerstein I; Stangler T; Schmiederer T; Fritsch C; Schiestl M BioDrugs; 2013 Oct; 27(5):495-507. PubMed ID: 23649935 [TBL] [Abstract][Full Text] [Related]
8. Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study. Nupur N; Chhabra N; Dash R; Rathore AS MAbs; 2018 Jan; 10(1):143-158. PubMed ID: 29200314 [TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry. Gahoual R; Biacchi M; Chicher J; Kuhn L; Hammann P; Beck A; Leize-Wagner E; François YN MAbs; 2014; 6(6):1464-73. PubMed ID: 25484058 [TBL] [Abstract][Full Text] [Related]
10. A rapid method for relative quantification of Segu Z; Stone T; Berdugo C; Roberts A; Doud E; Li Y MAbs; 2020; 12(1):1750794. PubMed ID: 32249667 [TBL] [Abstract][Full Text] [Related]
11. Multifaceted assessment of rituximab biosimilarity: The impact of glycan microheterogeneity on Fc function. Kang J; Kim SY; Vallejo D; Hageman TS; White DR; Benet A; Coghlan J; Sen KI; Ford M; Saveliev S; Tolbert TJ; Weis DD; Schwendeman SP; Ruotolo BT; Schwendeman A Eur J Pharm Biopharm; 2020 Jan; 146():111-124. PubMed ID: 31841688 [TBL] [Abstract][Full Text] [Related]
12. Physicochemical Characterization, Glycosylation Pattern and Biosimilarity Assessment of the Fusion Protein Etanercept. Montacir O; Montacir H; Springer A; Hinderlich S; Mahboudi F; Saadati A; Parr MK Protein J; 2018 Apr; 37(2):164-179. PubMed ID: 29411222 [TBL] [Abstract][Full Text] [Related]
13. Chemical Structure and Composition of Major Glycans Covalently Linked to Therapeutic Monoclonal Antibodies by Middle-Down Nuclear Magnetic Resonance. Peng J; Patil SM; Keire DA; Chen K Anal Chem; 2018 Sep; 90(18):11016-11024. PubMed ID: 30102512 [TBL] [Abstract][Full Text] [Related]
14. Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product. Lee KH; Lee J; Bae JS; Kim YJ; Kang HA; Kim SH; Lee SJ; Lim KJ; Lee JW; Jung SK; Chang SJ MAbs; 2018 Apr; 10(3):380-396. PubMed ID: 29469653 [TBL] [Abstract][Full Text] [Related]
15. Comparison of orthogonal chromatographic and lectin-affinity microarray methods for glycan profiling of a therapeutic monoclonal antibody. Cook MC; Kaldas SJ; Muradia G; Rosu-Myles M; Kunkel JP J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Aug; 997():162-78. PubMed ID: 26114652 [TBL] [Abstract][Full Text] [Related]
17. Development and validation of online SPE purification coupled to HILIC-fluorescence-MS analysis for the characterization of N-glycans. Helali Y; Bourez A; Marchant A; Vander Heyden Y; Van Antwerpen P; Delporte C Talanta; 2024 Apr; 270():125541. PubMed ID: 38101031 [TBL] [Abstract][Full Text] [Related]
18. Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review. Alsamil AM; Giezen TJ; Egberts TC; Leufkens HG; Vulto AG; van der Plas MR; Gardarsdottir H Eur J Pharm Sci; 2020 Nov; 154():105501. PubMed ID: 32739253 [TBL] [Abstract][Full Text] [Related]
19. The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development. Brady LJ; Velayudhan J; Visone DB; Daugherty KC; Bartron JL; Coon M; Cornwall C; Hinckley PJ; Connell-Crowley L MAbs; 2015; 7(3):562-70. PubMed ID: 25898160 [TBL] [Abstract][Full Text] [Related]